ALX ONCOLOGY HOLDINGS INC
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
ALXO$1.11-13.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2025 | 54,388,022 | $54 | $748,716 | $28 | $(722,817) | $25,981 |
| Issuance of common stock and pre-funded warrants in connection with equity offerings, net of underwriter discounts ($9,000) and issuance costs ($627) | 76,979,112 | 77 | 140,296 | — | — | 140,373 |
| Issuance of common stock from exercise of pre-funded warrants | 2,563,507 | 3 | — | — | — | 3 |
| Issuance of common stock under equity incentive plans | 602,672 | 1 | 669 | — | — | 670 |
| Issuance of common stock through ATM offering, net of commissions | 7,428 | — | 11 | — | — | 11 |
| Stock-based compensation | — | — | 2,509 | — | — | 2,509 |
| Unrealized loss on available-for-sale investments | — | — | — | (273) | — | (273) |
| Net loss | — | — | — | — | (17,927) | (17,927) |
| Balance as of March 31, 2026 | 134,540,741 | 135 | 892,201 | (245) | (740,744) | 151,347 |
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2024 | 53,052,912 | $53 | $734,412 | $275 | $(621,122) | $113,618 |
| Issuance of common stock under equity incentive plans | 125,920 | — | — | — | — | — |
| Issuance of common stock through ATM offering, net of commissions | 205,313 | — | 372 | — | — | 372 |
| Stock-based compensation | — | — | 5,216 | — | — | 5,216 |
| Unrealized loss on available-for-sale investments | — | — | — | (157) | — | (157) |
| Net loss | — | — | — | — | (30,754) | (30,754) |
| Balance as of March 31, 2025 | 53,384,145 | 53 | 740,000 | 118 | (651,876) | 88,295 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.